BRIEF-Benefits Of Pfizer-BioNTech COVID-19 Vaccine Clearly Outweigh Risks For Ages 5-11 Years In Most Scenarios- FDA Briefing Document

by Reuters
Saturday, 23 October 2021 03:18 GMT

Oct 22 (Reuters) -

* U.S. FDA PUBLISHES BRIEFING DOCUMENTS ON PFIZER COVID-19 VACCINE FOR CHILDREN AGED 5-11

* BENEFITS OF PFIZER-BIONTECH COVID-19 VACCINE CLEARLY OUTWEIGH THE RISKS FOR AGES 5-11 YEARS IN MOST SCENARIOS – FDA BRIEFING DOCUMENT

Our Standards: The Thomson Reuters Trust Principles.